By Michael Susin


GSK said it has sold a stake in Haleon valued around 978 million pounds ($1.24 billion), reducing its stake in the consumer-healthcare business to around 4.2%.

The British pharmaceutical giant said Wednesday that it has sold 300 million Haleon shares at an offer price of 326 pence a share. This represents a discount of 2.3% from Tuesday's closing price of 333.6 pence prior to the announcement.

U.S. pharma giant Pfizer also holds a 32% stake in Haleon, which was spun out of GSK and Pfizer's consumer-healthcare business.


Write to Michael Susin at


(END) Dow Jones Newswires

January 17, 2024 02:29 ET (07:29 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
過去 株価チャート
から 3 2024 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック
過去 株価チャート
から 4 2023 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック